Business Context and Reporting Period
Company: EyePoint Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 1, 2020
Event: Entry into a Material Definitive Agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreement Details
On August 1, 2020, the Company entered into a Commercial Alliance Agreement with ImprimisRx, LLC (a subsidiary of Harrow Health, Inc.). Key terms include:
- Scope: Imprimis granted non-exclusive rights to co-promote DEXYCU (dexamethasone intraocular suspension) 9% in the U.S. for post-operative inflammation following ocular surgery.
- Compensation: The Company will pay Imprimis a fee based on quarterly sales of DEXYCU exceeding predefined volumes to Imprimis customers.
- Operations: Co-promotion will be supervised by a commercialization committee and a joint steering committee with equal representation from both parties. Imprimis agreed to dedicate full-time sales representatives and contractors.
- Term: The agreement expires on August 1, 2025, subject to early termination.
Termination and Contingencies
The agreement includes specific termination rights for both parties:
- General Termination: Either party may terminate for uncured material breach or if DEXYU loses "pass-through" payment status.
- Imprimis Rights: May terminate for convenience (with extended notice) or if the Company undergoes a change of control.
- Company Rights: May terminate if Imprimis fails to achieve certain minimum sales levels during specified periods.
Investor Verification Checklist
- Verify the specific "predefined volumes" and fee calculation methodology for Imprimis compensation.
- Confirm the minimum sales levels required to prevent termination by the Company.
- Monitor the status of DEXYCU's "pass-through" payment status, as its loss triggers termination rights.
- Review the full text of the Commercial Alliance Agreement when filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2020.